Key Development
On September 3, 2026, the Ho Chi Minh City Department of Health announced a VND160 million administrative penalty against Dai Hung Pharmaceutical Co., Ltd., suspended the company’s cosmetics manufacturing activities until the required manufacturing eligibility certificate is obtained, and ordered the recall and destruction of all Thai Duong Tamanu Oil cosmetic products. The violations included manufacturing cosmetics without the required production eligibility certification and producing cosmetics that failed to meet quality standards.
The development is particularly notable because the product name has previously appeared in regulatory action. In July 2025, Vietnam’s Drug Administration ordered a nationwide recall and destruction of four batches of Thai Duong Tamanu Oil because of unclear origin and failure to meet declared volume specifications. Dai Hung Pharmaceutical was identified at that time as the organization responsible for placing the product on the market, while another company was listed as the manufacturer.
The latest enforcement action therefore raises a broader industry issue: whether cosmetic companies have sufficient governance across product lifecycle management, manufacturing compliance and supply-chain accountability.
Why It Matters
- Post-market surveillance is becoming a material business risk. Vietnam’s Drug Administration has intensified inspections across the pharmaceutical and cosmetics sectors in 2026, alongside multiple suspension, recall and destruction actions involving non-compliant cosmetics.
- Product notification alone is not sufficient. Companies must maintain compliance across manufacturing authorization, product quality, technical documentation and traceability throughout the commercial lifecycle.
- Compliance exposure extends beyond the factory. Brand owners, responsible market entities, distributors and supply-chain partners can all face commercial and reputational consequences when manufacturing or quality controls fail.
- Recall readiness is becoming part of the quality system. Companies need batch-level visibility across distribution channels and the operational ability to remove affected products rapidly when required.
Healthcare Insight Analysis
Healthcare Insight believes the most important figure in this case is not the VND160 million fine.
The larger cost of a compliance failure can arise from inventory destruction, product retrieval from pharmacies and retail channels, lost sales, consumer complaints, supplier remediation and reputational damage.
This has particular relevance to the rapidly expanding use of outsourced and contract manufacturing. A company that owns or commercializes a product cannot treat product quality as the factory’s responsibility alone.
Supplier qualification, quality agreements, batch documentation, release controls, change management, deviation handling and periodic audits increasingly need to sit at the center of the brand owner’s governance framework.
The fact that the same product name and responsible market entity had already been associated with a four-batch recall in 2025 makes the current development more strategically relevant. A recall should therefore not be treated simply as an operational incident to be closed. It should be treated as a quality signal capable of triggering a broader review of the product, manufacturing partners and underlying quality-management system.
This distinction is critical as Vietnam’s consumer-health and cosmetics markets become more sophisticated. Fast product launches and aggressive distribution can create growth, but they also increase exposure if quality systems fail to scale at the same pace.
Market Implications
In the near term, stronger post-market enforcement will likely increase compliance costs for cosmetics and consumer-health companies. Over time, however, it may accelerate the professionalization and consolidation of the market.
Companies with stronger QA/QC capabilities, reliable manufacturing partners, robust traceability systems and mature supplier governance are likely to gain an advantage over businesses competing primarily through rapid product launches and marketing.
Pharmacy chains, retailers and e-commerce platforms may also need to strengthen vendor due diligence — shifting from simply determining whether a product is commercially available to verifying its regulatory status, provenance and quality documentation.
The Thai Duong Tamanu Oil case should therefore be viewed as more than another product recall. It signals a broader transition in Vietnam’s healthcare and consumer-health ecosystem:
Compliance is moving from a back-office regulatory function to a core competitive capability.